Group 1 - Guotai Junan International received approval from the Hong Kong Securities and Futures Commission to upgrade its existing securities trading license to provide virtual asset trading services, leading to a significant market reaction with its stock price surging by 198.4% on June 25 [1] - The approval has sparked interest in the virtual asset trading market, with 40 institutions now authorized to offer such services, including Tianfeng International and Huafu Securities, indicating a growing recognition of virtual asset trading services in the market [1] - The event has created a ripple effect in the brokerage sector, with several Chinese brokerage stocks experiencing price changes, reflecting investor optimism about the expansion of virtual asset trading services [1] Group 2 - CITIC Securities announced plans to issue the first broker-dealer technology innovation bond in the interbank market, with an initial issuance size of 500 million yuan, marking a significant expansion of financing channels for brokerages [2] - The total issuance of technology innovation bonds by brokerages in the exchange market has surpassed 100 billion yuan, with major players like CITIC Securities and Guotai Haitong leading the way [2] - The issuance of these bonds is expected to bolster the capital strength and market confidence of the issuing brokerages, while also reflecting the industry's support for technology innovation [3] Group 3 - In June, the new fund issuance scale exceeded 90 billion yuan, with bond funds becoming particularly popular, indicating a shift in investor preference towards more stable investment strategies amid market volatility [4] - Mixed-asset FOF funds emerged as the top fund-raising category in June, while passive index products saw a decline in issuance, suggesting a cautious market sentiment among investors [4] - The changes in fund flows reflect an adaptive response to the current market conditions, with a trend towards conservative investment approaches [4] Group 4 - The first batch of 15 floating-rate funds has been established, attracting over 150 billion yuan in total subscriptions and more than 180,000 effective subscriptions, indicating strong market acceptance of these products [5] - The establishment of these floating-rate funds is expected to alleviate the decline in active equity fund issuance, thereby boosting investor confidence [5] - The successful launch of these funds may enhance the long-term development prospects for fund companies and increase interest in related sectors such as financial technology and fund distribution [6]

Group 1 - Western Cement (02233) opened over 5% higher, currently up 5.04% at HKD 1.46, with a trading volume of HKD 5.1596 million [1] - The company announced plans to sell its companies and assets in Xinjiang on June 24, 2025, with multiple transactions involving different buyers and sellers [1] - Transaction A involves the sale of equity for RMB 398 million, Transaction B for RMB 161.5 million, Transaction C for RMB 920.5 million, and Transaction D for RMB 170 million, all subject to adjustments [1] Group 2 - The target companies are wholly-owned subsidiaries of Seller A, primarily engaged in the manufacturing and sales of cement and related products, as well as waste management services [2] - The assets for sale were acquired and built between 2011 and 2020 and have positively contributed to the group's profitability in recent years [2] - The board believes that the net proceeds from the sale will be better utilized to repay part of the company's issued preferred notes (interest rate of 4.95%) and to release operating cash flow to support expansion projects, particularly in Africa [2]

公开资料显示，按2023年零售额计，颖通控股是中国（包括香港及澳门）除品牌所有者香水集团外最大 的香水集团。公品牌所有者香水集团不同，公司主要从事销售及分销从第三方品牌授权商采购的产品， 公司从中产生收入，及为该等品牌授权商进行市场部署，例如品牌管理，以及为其品牌设计及实施定制 的市场进入及扩张计划，公司并无从中产生收入。公司拥有庞大且多元化的品牌组合，不仅包括香水， 还包括彩妆、护肤品、个人护理产品、眼镜及家居香氛。公司在香水方面于中国(包括香港及澳门)取得 领先地位，乃因公司悠久的经营历史，公司在这些市场的香水行业中获得了广泛知识，并积累了相关专 业知识及丰富的资源为无数国际香水品牌进行分销及市场部署。 智通财经APP获悉，颖通控股(06883)首挂上市，公告显示，每股定价2.88港元，共发行3.334亿股股份， 每手1000股，所得款项净额约8.83亿港元。截至发稿，跌10.42%，报2.58港元，成交额1.14亿港元。 公司提供全面的销售及分销网络，涵盖中国(包括香港及澳门)大量的香水、护肤品、彩妆、个人护理产 品、眼镜及家居香氛的渠道。截至2025年3月31日，公司的产品于中国(包括香港及澳门)40 ...

智通财经6月26日电，香港恒生指数开盘跌0.53%，恒生科技指数跌0.52%，中国月子中心圣贝拉香港首 日挂牌开盘报8.45港元，招股价为6.58港元。 ...

Core Viewpoint - Zhou Shifu's stock opened over 10% higher on its first day of trading in Hong Kong, currently priced at 26.7 HKD [1] Company Overview - Zhou Shifu was founded in 2004 and is recognized as one of China's leading jewelry brands [1] - The company is primarily engaged in the research and design, production and processing, chain sales, and brand operation of jewelry [1] - Zhou Shifu offers gold jewelry products and diamond-set jewelry through both offline stores and online sales channels [1]

Core Viewpoint - The significant rise in the stock price of Guotai Junan International Holdings Limited (1788.HK) is attributed to the approval of its upgraded securities trading license, allowing it to provide virtual asset trading services, marking a new high since July 2015 [1][4]. Group 1: Company Developments - Guotai Junan International's stock price surged to HKD 3.7 per share, reflecting a 198.39% increase [1]. - The upgrade of the trading license enables clients to trade cryptocurrencies and stablecoins directly on the company's platform, enhancing its business scope [4]. - Guotai Junan International becomes the first Chinese broker in Hong Kong to offer comprehensive virtual asset trading services, including trading, advisory, and issuance of related products [4]. Group 2: Market Analysis - Analysts have positively evaluated the company's early entry into the virtual asset sector, with expectations of further upgrades among brokers with international business subsidiaries [4]. - The approval process for Guotai Junan International exceeded market expectations, indicating a proactive approach in the evolving regulatory landscape [4]. Group 3: Industry Context - Hong Kong's regulatory stance on virtual assets has shifted from cautious to open since 2022, with significant policy developments supporting the industry [5]. - The passage of the Stablecoin Bill in May 2025 reflects Hong Kong's commitment to advancing its virtual asset regulatory framework [5]. - Hong Kong is positioning itself as a global hub for virtual assets, leveraging its financial infrastructure and the advantages of the Guangdong-Hong Kong-Macao Greater Bay Area [5].

就建议分拆而言，华夏基金(作为公募基金管理人)将设立公募基金作为封闭式公开上市基础设施证券投 资基金，并负责其日常营运。目前，预计公募基金将募集人民币13.55亿元。于建议上市时，本集团将 认购已发行基金份额总数约20%。就建议分拆而言及根据适用中国法律及法规的规定，资产支持专项计 划将由资産支持专项计划管理人设立。于建议上市完成后，公募基金将动用所得款项认购资产支持专项 计划的全部权益，其后，资産支持专项计划将动用认购款项向本集团收购项目公司的全部权益、偿还项 目公司的债务及支付公募基金及资产支持专项计划成立、交易费用。于有关收购完成后，项目公司将由 基础设施REIT持有100%权益，并将不再为公司的附属公司。于建议分拆后，基础设施REIT将不会成为 公司的附属公司，亦将不会併入公司的财务账目。 智通财经APP讯，中国海外发展(00688)发布公告，于2025年6月25日，华夏基金及中信证券向中国证监 会及深圳证券交易所提交了公募基金注册及上市的申请材料。公司已向联交所提交应用指引第15项申请 及就豁免严格遵守应用指引第15项第3(f)段有关保证配额要求的申请，且联交所已授出该豁免，并确认 公司可进行建议分 ...

Group 1: Brain-Computer Interface Standards - The National Standard for Non-Invasive Medical Devices Using Brain-Computer Interface Technology is open for public consultation, aiming to establish performance indicators and testing methods for such devices [1] - The standardization is expected to enhance international cooperation and improve regulatory efficiency, addressing the rapid development in the non-invasive neural modulation sector [1] Group 2: Pharmaceutical Industry Innovation - The head of the National Medical Products Administration emphasized the importance of supporting drug and medical device R&D innovation to strengthen China's pharmaceutical industry [2] - Key strategies include early intervention, tailored guidance for enterprises, and promoting international multi-center clinical trials to synchronize the development and approval of innovative drugs and devices [2][3] Group 3: Clinical Trials and Approvals - Shenzhou Cell announced that its product SCTB39G received approval for clinical trials in advanced solid tumors [4] - Hanyu Pharmaceutical's subsidiary received approval for the listing of the raw material drug Acetate Degarelix, which is used for treating advanced prostate cancer [6] Group 4: Market Expansion and IPOs - Kangzhe Pharmaceutical plans a secondary listing in Singapore, reflecting a trend of pharmaceutical companies expanding into Southeast Asian markets [7] - Lianya Pharmaceutical's IPO application has been accepted, focusing on complex drug formulations and high-end generic drugs [9] Group 5: Strategic Collaborations - Bayer and Tsinghua University signed a strategic cooperation agreement to enhance research in various medical fields, aiming to accelerate drug innovation [11][12] Group 6: Clinical Trial Developments - Fuhong Hanlin announced the first patient enrollment in a bridging clinical trial for its drug H, which is approved for first-line treatment of small cell lung cancer in multiple countries [13] Group 7: Corporate Leadership Changes - Fosun Pharma held a shareholder meeting to elect new board members, appointing Chen Yuqing as chairman and Liu Yi as CEO [14]

智通财经6月26日电，众安在线在港交所公告， 根据一般授权配售新H股，配售价每股18.25港元，配售 所得款项总额预计合共约39.2亿港元。 ...

公告表示，锚定"成长为国际一流的生物制药企业"的长期愿景，公司依托强大的研发平台与丰厚的创新 管线，正步入全球创新的新成长周期。创新管线的全球化布局已逐步成为公司潜在重要的增长引擎，并 展现出其核心竞争力。公司相信，本次配售事项将更好地支持公司的全球化布局，并赋予公司在管线开 发上更多支持和灵活性。这将有助于充分并加速实现公司丰厚管线的价值潜能，为公司与股东创造可持 续的长期回报。 配售股份将根据一般授权予以发行。配售股份的数目相当于本公告日期已发行股份(不包括库存股份)总 数的约3.33%；及完成配售事项后经扩大已发行股份(不包括库存股份)总数的约3.22%。假设全部配售股 份获悉数配售及认购，则配售事项所得款项总额预期约为43.098亿港元，而所得款项净额将约为42.654 亿港元。本次配售事项所得净款项将用于：(i)约90%用于推进公司丰厚的临床及临床前重点创新管线的 全球研发，以及用于公司的全球设施设备布局；及(ii)约10%将用于公司日常运营。 格隆汇6月26日丨信达生物(01801.HK)发布公告，2025年6月26日(交易时段前)，公司与联席配售代理(即 摩根士丹利及高盛)订立配售协议，据此，公 ...